跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PALBOCICLIB SANDOZ CAPSULE 125MG - HSA Drug Approval Details
Approvals
/
HSA
/
PALBOCICLIB SANDOZ CAPSULE 125MG
Approved
THERAPEUTIC
PALBOCICLIB SANDOZ CAPSULE 125MG
Aizant Drug Research Solutions Pvt Ltd.
🇸🇬 Health Sciences Authority
Approval Date
May 9, 2024
Approval ID
5dd5704a11c4c5eb
Company
Aizant Drug Research Solutions Pvt Ltd.
Type
Therapeutic
Approval Details
Approval Id
5dd5704a11c4c5eb
Drug Name
PALBOCICLIB SANDOZ CAPSULE 125MG
Product Name
PALBOCICLIB SANDOZ CAPSULE 125MG
Approval Number
SIN17007P
Approval Date
2024-05-09
Registrant
NOVARTIS (SINGAPORE) PTE LTD
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
CAPSULE
Route Of Administration
ORAL
Atc Code
L01EF01
Pharma Manufacturer Name
NOVARTIS (SINGAPORE) PTE LTD
Company Detail Path
/organization/novartis-singapore-pte-ltd
Active Ingredients
Palbociclib
125.00 mg
Palbociclib
125.00 mg
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
May 9, 2024
Approval ID
5dd5704a11c4c5eb
Type
Therapeutic
Back to HSA Approvals